2025-11-16 - Analysis Report
Okay, here's an analysis of UnitedHealth Group Inc (UNH) based on the data provided.

## UNH (UnitedHealth Group Inc) Analysis

**Company Overview:** UnitedHealth Group Inc. is a diversified healthcare company providing health benefits and healthcare services.

**1. Performance vs. S&P 500 (VOO)**

*   **Cumulative Return (UNH):** -18.58%
*   **Cumulative Return (VOO):** 98.45%
*   **Absolute Divergence:** -117.03% (UNH underperformed VOO by a significant margin).
*   **Relative Divergence:** 7.7 (Indicates that UNH's underperformance is near the lower end of its historical range compared to VOO).

**Alpha/Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha  | Beta  | Cap(B) |
| :----------- | :------ | :------ | :----- | :---- | :----- |
| 2015-2017  | 58.0%  | 66.4%  | 30.0%  | 0.0   | 206.3  |
| 2016-2018  | 41.0%  | 70.4%  | 26.0%  | -0.0  | 233.1  |
| 2017-2019  | 36.0%  | 73.8%  | 14.0%  | 0.2   | 275.1  |
| 2018-2020  | -43.0% | 81.2%  | -67.0% | 0.5   | 328.2  |
| 2019-2021  | 16.0%  | 81.2%  | -31.0% | 1.5   | 469.9  |
| 2020-2022  | -1.0%  | 81.2%  | 0.0%   | 1.5   | 496.2  |
| 2021-2023  | 24.0%  | 80.8%  | 23.0%  | 0.4   | 492.7  |
| 2022-2024  | -27.0% | 78.8%  | -47.0% | 0.3   | 473.4  |
| 2023-2025  | -61.0% | 79.8%  | -124.0% | 1.2   | 301.2  |

**Analysis:**

*   **CAGR and MDD:** The historical performance shows a wide range of returns, with some periods of very high growth (e.g., 2015-2017) and other periods of significant losses (e.g., 2023-2025). The Maximum Drawdown (MDD) is consistently high, indicating substantial volatility.
*   **Alpha:**  Alpha is generally positive in the earlier periods, indicating outperformance relative to the market. However, it turns negative in recent years, suggesting underperformance. The significant negative alpha in 2023-2025 suggests a significant underperformance compared to what would be expected based on market movements.
*   **Beta:** Beta fluctuates. The later years beta values close to 1 suggests UNH's price is highly correlated with the market.

**2. Recent Price Action**

*   **Current Price:** $321.86
*   **Previous Close:** $332.52
*   **Change:** -$3.21 (Recent price drop)
*   **5-day Moving Average:** $328.49
*   **20-day Moving Average:** $343.51
*   **60-day Moving Average:** $340.90

**Analysis:**

*   The stock is trading below all three moving averages, suggesting a short-term downtrend. The significant price drop from the previous close further reinforces this bearish signal.

**3. Technical Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommendation)
*   **RSI:** 24.96 (Oversold)
*   **PPO:** -0.63 (Negative, suggesting a downtrend)
*   **Hybrid Signal:** Cash_79%_Sell 79.7% of holdings (suggests a strong sell signal based on risk assessment)
*   **Recent (20-day) Relative Divergence Change:** 1.9 (Positive, indicating a potential short-term uptick in relative performance but must be very careful as it has a strong SELL signal now)
*   **Expected Return:** -185.1% (Significantly negative, indicating a potentially negative expected return compared to the S&P 500 over a long-term investment horizon).

**Analysis:**

*   The RSI indicates the stock is oversold, which could lead to a potential bounce. However, the PPO and Hybrid Signal point to a continuing downtrend and suggest selling the stock. The MRI indicates medium investment recommendation, but it should be noted that the hybrid signal is strong SELL. The very negative expected return is a major concern, suggesting that UNH is expected to significantly underperform the market in the long run.

**4. Recent News & Significant Events**

*   **David Tepper's Firm:** Reduced its position in UnitedHealth Group Inc by -10.87%
*   **Analyst Blog:** UNH is highlighted alongside Apple and Procter & Gamble.
*   **Healthcare Stocks:**  General discussion about healthcare stocks' performance.

**Analysis:**

*   The news about David Tepper's firm reducing its stake is a negative signal. The other headlines are more generic but the reduction in portfolio is notable.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean: 2.00)
*   **Target Price (avg/high/low):** 385.40 / 440.00 / 198.00

**Analysis:**

*   Despite the recent negative performance, analysts maintain a "Buy" rating with a significant average target price ($385.40). However, the wide range between the high and low target prices indicates uncertainty among analysts.

**5. Recent Earnings Analysis:**

| Date       | EPS  | Revenue        |
| :----------- | :--- | :------------- |
| 2025-10-28 | 2.59 | 113.16 B$      |
| 2025-08-11 | 3.76 | 111.62 B$      |
| 2025-05-07 | 6.9  | 109.58 B$      |
| 2024-11-04 | 6.56 | 100.82 B$      |
| 2025-10-28 | 6.56 | 100.82 B$      |

**Analysis:**

*   Revenue has been generally increasing, but recent EPS figures have been volatile. This discrepancy between revenue growth and EPS could be a concern.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue      | Profit Margin |
| :------------- | :----------- | :------------ |
| 2025-09-30   | \$113.16B    | 18.24%        |
| 2025-06-30   | \$111.62B    | 17.93%        |
| 2025-03-31   | \$109.58B    | 21.70%        |
| 2024-12-31   | \$100.81B    | 21.14%        |
| 2024-09-30   | \$100.82B    | 22.84%        |

**Capital and Profitability:**

| Quarter      | Equity       | ROE      |
| :------------- | :------------ | :------- |
| 2025-09-30   | \$95.79B     | 2.45%   |
| 2025-06-30   | \$94.72B     | 3.60%   |
| 2025-03-31   | \$95.04B     | 6.62%   |
| 2024-12-31   | \$92.66B     | 5.98%   |
| 2024-09-30   | \$94.53B     | 6.41%   |

**Analysis:**

*   Revenue has been consistently growing. However, profit margins have fluctuated and generally trending downwards. ROE has also declined significantly, indicating a decrease in the company's ability to generate profit from equity.

**7. Overall Assessment:**

UnitedHealth Group Inc. (UNH) is currently facing significant headwinds. While revenue is growing, profitability metrics like profit margin and ROE are declining. The stock has significantly underperformed the S&P 500, and technical indicators suggest a strong sell. Analyst opinions remain positive, but target price ranges are wide. The reduction in portfolio by David Tepper further reinforce SELL position

**Recommendations:**

Given the recent underperformance, negative technical signals, and declining profitability, a **SELL** recommendation seems warranted. Although analysts have BUY opinions, the negative expected return and recent news/actions are more concerning.
